Targeting the CXCL1–CXCR2 axis, anti-OPN, anti-Ly6G, and DNase I treatments phenocopied each other in reducing HCC lung metastatic incidences in vivo (34). The gene discussed is CXCL1; the disease is hepatocellular carcinoma.